Restylane Dermal Fillers

Know our NASHAs from our OBTs to create a personalised signature look with Restylane® hyaluronic acid fillers

What is the science behind Restylane®? Restylane® is the original non-animal stabilised hyaluronic acid dermal filler offering an extensive range of effects.1-6 The complementary range of Restylane® dermal fillers can be tailored to any individual look to enhance and refine facial features.

What is the history of Restylane®? Galderma launched Restylane®, the world’s first non-animal hyaluronic acid filler, in Europe in 1996 and secured the first FDA approval in 2003. Experience is built on more than 50 million treatments, 7 over two decades of safety data, and a robust clinical trial programme characterising the efficacy, safety profiles, satisfaction, and durability of Galderma’s hyaluronic acid-based treatments. Restylane® is the most well-established filler on the market with multiple decades of experience.7

NASHA for lifting and precision OBT for contouring and expression

Firmer gels with minimal modification. Utilises the natural entanglement of hyaluronic acid strands creating unique gel properties with less synthetic cross-linking.12

• Intended for projection and structure8 • Suited for enhancing cheeks and filling lips, wrinkles and folds • When precision is needed8,13

NASHA can be used for nose chin, and jawline. Soft gels with high flexibility and varied degrees of cross-linking and calibration creating a range of gels providing natural looking effects.3,14

• Intended for contouring and volumisation of the mid-face. • Suited for dynamic areas allowing for natural animation such as lips, nasolabial folds, and perioral lines.15,16 WHY is Restylane® the world’s most diverse range of HA fillers? The Restylane® range utilises two technologies to stabilise hyaluronic acid into a gel form. When injected, it adds volume to smooth wrinkles and enhances facial balance where needed. Restylane® dermal fillers contain hyaluronic acid that has been stabilised with a cross-linking technology. This makes the chains of the hyaluronic acid molecules form a three-dimensional network that is remarkably similar to naturally occurring hyaluronic acid but does not degrade at the same rate. The Restylane® range delivers results that last up to 24 months with one treatment.

Types of filler

1. Restylane® NASHA gels

The Restylane® Non-Animal Stabilised Hyaluronic Acid (NASHA™) gels are firmer with minimal modification and are used to create projection and definition. The Restylane® NASHA gels are very close to the natural composition of hyaluronic acid. They offer a precise and pronounced lift, suitable for lifting the cheeks, enhancing the jawline or chin, or reducing the appearance of wrinkles.10

2. Restylane® OBT gels

The Restylane® Optimal Balance Technology (OBT™) gels are softer and more flexible enabling smoother integration into the tissue for naturallooking results. They are used, for example, to add volume in the mid-face, or to enhance contours for patients. Restylane® OBT gels are also used for dynamic areas of the face such as lips and cheek wrinkles.3,4,11 OBT gels are most useful for contouring and expression.

REFERENCES

1. Data on File. REF MA-33939. Galderma Ltd. 2. Öhrlund A. Poster presented at AMWC 2019. 3. Philipp-Dormston WG et al. Dermatol Surg 2018;44(6):826-832. 4. Data on File. REF MA-34675. Galderma Ltd. 5. Segura S et al. J Drugs Dermatol 2012;11(1 Suppl:s5–s8). 6. Tezel A, Fredrickson GH. J Cosmet Laser Ther 2008;10:35–42. 7. Data on File. REF MA-39680. Galderma Ltd. 8. Andriopoulos B et al. Poster presented at AMWC 2019. 9. Data on File. REF MA-39364. Galderma Ltd. 10. Kablik J et al. Dermatol Surg 2009;35(Suppl1):302–312. 11. Data on File. REF MA-33947. Galderma Ltd. 12. Micheels P et al. J Drugs Dermatol 2016;15(5):600-606. 13. Lundgren B et al. J Drugs Dermatol 2018;17(9)982-986. 14. Data on File. REF MA-43049. Galderma Ltd. 15. Nikolis A et al. Aesth Surg J Open Forum 2020;2(1) ojaa005. 16. Solish N et al. J Cosmet Dermatol 2019;18(2):738-746.

For more information about the Restylane Range please contact your Galderma Key Account Manager or Medfx.

ADVERSE EVENTS SHOULD BE REPORTED

For Ireland, suspected adverse events can For the UK, report forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. be reported via HPRA Pharmacovigilance, www.hpra.ie; Adverse events should also be reported to Galderma (UK) Ltd. Email: Medinfo.uk@galderma.com Tel: +44 1 923 208950 This article is sponsored by Galderma (UK) Ltd.